



International Conference on the Management of Patients with Viral Hepatitis

Organised by Pr Patrick Marcellin

Organising Committee:

Tarik Asselah,

Nathalie Boyer, Olivier Lada, Michelle Martinot-Peignoux

Hôpital Beaujon, APHP

Université Paris - Diderot

INSERM CRB3

14 & 15 January 2013

PARIS - Palais des Congrès



www.aphc.info



Dear colleagues,

We are pleased to announce that this year the **6th Paris Hepatitis Conference** (PHC) will take place in January, 2013.

The meeting will once again provide the state of the art on the management of patients with hepatitis B and hepatitis C by outstanding international experts who will present the most recent data as well as the clinical applications in this area. Last year the meeting was especially devoted to hepatitis C and the recent spectacular innovations made in the management of that disease thanks to the development of new therapies.

In 2012, triple therapy has become the standard of care for hepatitis C in some countries. However, this treatment is not available in most countries and is not effective in patients with the non-1 genotype. A number of new drugs are currently being developed to improve efficacy and tolerance.

At present, the attention of clinicians is turned in an exciting new direction: interferon free therapy that will be effective in all genotypes. This option raises an important issue that will be at the heart of discussions during the PHC conference in 2013: Which patients should be treated in 2013 and how can we increase their chance of a cure? Which patients can be treated later, based on future options?

At the same time, the PHC 2013 conference, as in the past, will address and focus upon Hepatitis B. We will spend a full day discussing results on the long-term outcome of patients receiving the most potent available antiviral drugs. We will also assess the issue of quantifying HBsAg, and its role as a new tool for predicting the severity of disease and response to therapy. The optimal management of special populations and difficult situations will be extensively discussed: pregnancy, co-infections, cirrhosis...

As in previous PHCs, we will privilege interactive discussions and many specific working luncheons addressing the management of real-life patients.

Finally, the ultimate goal of PHC 2013 is to review the most current knowledge and discuss their therapeutic applications with the most experienced experts to provide optimal therapy and the best chance of cure to as many patients as possible, worldwide.

I look forward to welcoming you to Paris.

All the best,

Professor Patrick Marcellin

President of the 6th Paris Hepatitis Conference

HEPATITIS C - Amphitheatre Bleu

08.30 **Introduction: Treatment of hepatitis C: the cure** *Patrick Marcellin (France)*

08.40 **Research in viral hepatitis: the French ANRS experience** *Jean-François Delfraissy (France)*

08.50 - 09.20 **State of the art lecture** *Chairman: Tarik Asselah (France)*
 ■ Targets for HCV therapy: clinical applications *Charles Rice (USA)*

09.20 - 10.30 **How to optimize current therapy of G1 patients**
Chairpersons: Nezam Afdhal (USA) and Massimo Colombo (Italy)

09.20 ■ Optimal treatment with telaprevir *Ira Jacobson (USA)*
 09.35 ■ Optimal treatment with boceprevir *Michael Manns (Germany)*
 09.50 ■ Predictors of response *Antonio Craxi (Italy)*
 10.05 ■ Management of side effects *Sam Lee (Canada)*
 10.20 ■ Round table discussion

☕ 10.40 - 11.00 **Coffee break**

11.00 - 12.30 **How to optimize current therapy of non G1 patients**
Chairpersons: Mark Thursz (UK) and Jake Liang (USA)

11.00 ■ Genotype 2 *Alessio Aghemo (Italy)*
 11.15 ■ Genotype 3 *Graham Foster (UK)*
 11.30 ■ Genotype 4 *Gamal Esmat (Egypt)*
 11.45 ■ Round table discussion

12.00 - 12.30 **State of the art lecture** *Chairman: Patrick Marcellin (France)*
 ■ Milestones in therapy of liver diseases *Jenny Heathcote (Canada)*

12.30 - 14.30 **Interactive Luncheons**

14.30 - 16.00 **Difficult to treat patients**
Chairpersons: Michael Fried (USA) and Masao Omata (Japan)

14.30 ■ Cirrhotic patients *Marc Bourlière (France)*
 14.45 ■ Transplant patients *Didier Samuel (France)*
 15.00 ■ HIV co-infected patients *Mark Sulkowski (USA)*
 15.15 ■ Round table discussion

☕ 15.40 - 16:00 **Coffee break**

16.00 - 17.20 **New therapeutic strategies**
Chairpersons: Rafael Esteban (Spain) and Donald Jensen (USA)

16.00 ■ Best strategies for global HCV eradication *Raymond Schinazi (USA)*
 16.15 ■ 2nd generation protease inhibitors *David Nelson (USA)*
 16.30 ■ Polymerase inhibitors *Stefan Zeuzem (Germany)*
 16.45 ■ IFN-free regimens *Tarik Asselah (France)*
 17.00 ■ Round table discussion

17.20 - 17.50 **Controversy: F1/F2 patients: treat or wait?** *Chairman: Graham Foster (UK)*
 ■ Treat: *Mitchell Shiffman (USA)* Wait: *Yves Benhamou (France)*

17.50 **Conclusion** *Patrick Marcellin (France)*

18.00 **Ajournement**

19.30 **Congress dinner**

PROGRAMME OF THE WORKING LUNCHEONS

For people not registered to the working luncheons, regular lunches are also organized in Salons Concorde (Level 4)

HEPATITIS C

January 14th, 2013 from 12:30 to 14:30

Room 242B - Level 2

1. G1 naive patients: how to optimize treatment?

Chairs: Antonio Craxi (Italy) and Vlad Ratziu (France)

Speakers: Raluca Pais (France)

Vasily Isakov (Russia)

Room 241 - Level 2

2. Resistance to protease inhibitors: is it a real issue?

Chair: Raymond Schinazi (USA)

Speakers: Philippe Halfon (France)

Olivier Lada (France)

Room 243 - Level 2

3. G4 patients: how to optimize treatment?

Chair: Graham Foster (UK)

Speakers: Gamal Esmat (Egypt)

Ahmed El Ray (Egypt)

Room 252A - Level 2

4. How to manage relapsers and non-responders to PEG IFN + RBV therapy?

Chairs: Eugene Schiff (USA) and Laurent Castera (France)

Speakers: Lawrence Serfaty (France)

Maria Buti (Spain)

Room 242A - Level 2

5. Triple therapy with telaprevir or boceprevir: management of side effects?

Chair: Michael Fried (USA)

Speakers: Vincent Di Martino (France)

Peter Ferenci (Austria)

Room 251 - Level 2

6. Future therapeutic strategies with direct acting antivirals

Chair: Tarik Asselah (France)

Speakers: Robert Flisiak (Poland)

Liesl Hagan (USA)

Room 252B - Level 2

7. Comment optimiser le traitement des malades naïfs ?
(French speaking luncheon)

*Chairs: Mihai Voiculescu (Romania) and
Christophe Hézode (France)*

Speakers: Najet Belhadj Brik (Tunisia)

Raymond Sayegh (Liban)

Room 253 - Level 2

8. Comment optimiser le traitement des rechuteurs et non répondeurs (French speaking luncheon)

*Chairs: Mustapha Benazzouz (Morocco) and
Daniel Dhumeaux (France)*

Speakers: Albert Tran (France)

Jean-Pierre Bronowicki (France)

HEPATITIS B

January 15th, 2013 from 12:30 to 14:30

Room 242B - Level 2

1. Should immunotolerant and inactive carriers be treated?

Chair: Pietro Lampertico (Italy)

Speakers: Adrian Gadano (Argentina)

Sam Lee (Canada)

Room 241 - Level 2

2. Long term impact of treatment on the outcome of the liver disease?

Chair: Yun-Fan Liaw (Taiwan)

Speakers: Philippe Mathurin (France)

Yazdan Yazdanpanah (France)

Room 243 - Level 2

3. First line therapy: interferon or analogue?

Chair: Massimo Colombo (Italy)

Speakers: George Lau (Hong Kong) - Interferon

Thomas Berg (Germany) - Analogue

Room 252A - Level 2

4. Treatment of patients with resistant HBV?

Chair: Geoffrey Dusheiko (UK)

Speakers: George Papatheodoridis (Greece)

Vincent Leroy (France)

Room 251 - Level 2

5. The clinical applications of HBsAg quantification

Chair: Henry Chan (Hong Kong)

Speakers: Michelle Martinot-Peignoux (France)

Philippe Halfon (France)

Room 252B - Level 2

6. Fibrosis staging: liver biopsy or indirect markers?

Chairs: Nezam Afdhal (USA) and Pierre Bedossa (France)

Speakers: Victor De Ledinghen (France)

Ana Carolina Cardoso (Brazil)

Room 253 - Level 2

7. Interféron ou analogue ?

(French speaking luncheon)

*Chairs: Jean-Pierre Zarski (France) and
Zahari Krastev (Bulgaria)*

Speakers: Rami Moucari (United Arab Emirates)

Rachid Ould Gougam (Algeria)

Room 242A - Level 2

8. Faut-il traiter les immunotolérants et les porteurs inactifs ? (French speaking luncheon)

Chairs: Christian Trépo (France)

and Jean-François Cadranel (France)

Speakers: Adriana Popescu (Romania)

Rhimou Alaoui (Morocco)

HEPATITIS B

- 08.30 Introduction: HBV: viral control or clinical cure? *Patrick Marcellin (France)*
- 08.40 - 10.00 The control of HBV related liver disease
Chairpersons: Henry Chan (Hong Kong) and Antonio Craxi (Italy)
- 08.40 ■ Impact of therapy on the outcome of CHB *Yun-Fan Liaw (Taiwan)*
 08.55 ■ Optimal management of patients with resistance *Fabien Zoulim (France)*
 09.10 ■ HBsAg quantitation ; clinical applications *Michelle Martinot-Peignoux (France)*
 09.25 ■ Round table discussion
- ☕ 10.00 - 10.30 Coffee break
- 10.30 - 11.30 Optimal therapy of HBeAg-positive chronic hepatitis B
Chairpersons: Jia-Horng Kao (Taiwan) and Eugene Schiff (USA)
- 10.30 ■ Why do I treat my patient with a NUC? *Ji Dong Jia (China)*
 10.45 ■ Why do I treat my patient with pegylated IFN? *Geoffrey Dusheiko (UK)*
 11.00 ■ Round table discussion
- 11.30 - 12.30 Optimal therapy of HBeAg-negative chronic hepatitis B
Chairpersons: Seng Gee Lim (Singapour) and Feruccio Bonino (Italy)
- 11.30 ■ Why do I treat my patient with a NUC? *George Papatheodoridis (Greece)*
 11.45 ■ Why do I treat my patient with pegylated IFN? *Pietro Lampertico (Italy)*
 12.00 ■ Round table discussion
- 12.30 - 14.30 Interactive Luncheons
- 14.30 - 16.30 Therapy in special populations
Chairpersons: Jean-Pierre Zarski (France) and Massimo Levrero (Italy)
- 14.30 ■ Acute hepatitis B and HBV reactivation *Shiv Kumar Sarin (India)*
 14.45 ■ Cirrhosis *Thomas Berg (Germany)*
 15.00 ■ Immuno-suppressed patients *Stanislas Pol (France)*
 15.15 ■ Round table discussion
- 15.30 ■ Pregnancy *Teerha Piratvisuth (Thailand)*
 15.45 ■ Hepatitis delta *Mario Rizzetto (Italy)*
 16.00 ■ The role of combination therapy *Jorg Petersen (Germany)*
 16.15 ■ Round table discussion
- 16.30 Conclusion: the next steps *Patrick Marcellin (France)*
- 16.45 Ajournement

GENERAL INFORMATION

CONFERENCE DATES AND VENUE

From Monday 14th
to Tuesday 15th January 2013
At the “Palais des Congrès”
2, place de la Porte Maillot
75017 Paris – France
Metro and RER station:
“Porte Maillot”

CONFERENCE REGISTRATION DESK

14th & 15th January, from 7:30 am.
Welcome desks are organized on level 2 of
the Palais de Congrès in Foyer Bleu next to
the Amphitheatre Bleu. You will be able to
register on site, retrieve your access badge,
congress bag and proceedings.

CONGRESS OFFICE

Quadrature Santé / PHC 2013
43 rue des Tilleuls
92100 Boulogne-Billancourt
Phone: +33 1 41 10 46 65
Fax: +33 1 41 10 46 69
Contact: contact@phc-congress.com
www.aphc.info

CONGRESS HOTELS

Concorde Lafayette Hotel
3 place du Général Koenig
75017 Paris
Tel : + 33 (0)1 40 68 50 68

Méridien Etoile Hotel
81 boulevard Gouvion St-Cyr
75 017 Paris
Tel: +33 (0)1 40 68 34 34

CONGRESS DINNER

Monday 14th January at the
Salons du Pré Catelan
Bois de Boulogne - Route de Suresnes
75016 PARIS

Buses will leave from the Palais des
Congrès at 7:30 p.m.
Dress code : cocktail attire

CME CONTINUOUS MEDICAL EDUCATION ACCREDITATION

The “APHC” is accredited by the European
Accreditation Council for Continuing
Medical Education (EACME) to provide
the following CME activity for medical
specialists.

The 6th Paris Hepatitis Conference is
designated for a maximum of (or “for up
to”) 12 European CME credits (ECMEC).

LIVER INTERNATIONAL

The PHC Liver International Supplement is
available online at the following address:
<http://blackwellpublishing.com>

The conference is supported by:
Roche, Janssen, Gilead, MSD,
Novartis, BMS,
Alios BioPharma

LUNCHEES

2 types of lunches are organised
each day:

- *Working Luncheons* (Level 2).
- The number of seats is limited.
- *Regular luncheons* are organised in
Salons Concorde (Level 4).

METRO and RER

The metro station (line 1) and RER station
(line C) are located on level -1 of the
Palais des Congrès: Porte Maillot station.
The Conference will be held in
Amphitheatre Bleu on level 2.

OFFICIAL LANGUAGE

The official language
of the conference is English.

